Modica S, Straub LG, Balaz M, Sun W, Varga L, Stefanicka P, Profant M, Simon E, Neubauer H, Ukropcova B, Ukropec J, Wolfrum C
Additional studies are needed to define the participation of increased energy expenditure on the weight loss induced by GLP-1RAs
Through ongoing professional guidance, the journey from frequent acute episodes to long-term stability becomes achievable, empowering individuals to regain energy, reduce complications, and enhance quality of life
Retatrutide's GCGR agonism is the most likely pharmacological explanation - glucagon has documented effects on sensory and autonomic nervous system function - and the dose-dependence (absent at lower doses, material at 9 and 12 mg) supports that hypothesis
This discovery, more than any other, has led to the therapeutic translation of the basic science of incretin biology and the development of GLP-1 agonists resistant to degradation by DPP-4 and of selective inhibitors of DPP-4 activity as therapeutic agents